Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Window: India Extends Price Cap Exemption To Foreign Innovation

Executive Summary

Innovative medicines developed abroad and patented and launched in India could be entitled to unfettered pricing for a five-year period under new norms announced in the country. Orphan drugs could also qualify for such exemption, much to the concern of healthcare activists.

You may also be interested in...



India Cuts Prices Of 463 Anticancers But Loose Ends Remain

Prices of over 400 anticancers have been revised downwards in India by the capping of trade margins, but some healthcare activists say that real benefits for patients could still be elusive. Pharma is also required to maintain production volumes in the new scenario – will it pinch?

India Government Procurement Preference Norms – Rising Local Flavour

Increasing local content requirements have been stipulated in the public purchase preference norms for medicines in India. Backward-integrated Indian firms stand to gain but progressive localization requirements for drugs not made in India appear to be a tough ask.

India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)

2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel